Company Intelligence

Ditto Biosciences

Ditto Bio discovers drugs for autoimmune diseases by harnessing parasite biology. Viruses, ticks, and worms have experimented over millions of years to create proteins that control the human immune system. We use AI to identify these…

In this profile

Quick Facts

  • Founded 2026
  • Headquarters San Francisco, United States
  • Country United States
  • Industry AI in Healthcare
  • Company Type Early
  • Status Active
  • Website Official site
  • Last Reviewed Aug 2026

Executive Summary

Ditto Bio discovers drugs for autoimmune diseases by harnessing parasite biology. Viruses, ticks, and worms have experimented over millions of years to create proteins that control the human immune system. We use AI to identify these proteins and engineer them into next-generation autoimmune therapies.

Our team is three PhD scientists from UCSF, UCSD, and UC Berkeley who have worked together for 3+ years in biotech. We have deep expertise in parasite biology, computational biology, and software for AI-based protein structure prediction

Why It Matters

Evolutionary intelligence for autoimmune disease

Recent Developments

  1. 2026 Company founded

    Ditto Biosciences was founded in 2026 per the company profile source on file.

    Source

Connected Reports

Connected Insights

Industries

Ditto Bio discovers drugs for autoimmune diseases by harnessing parasite biology. Viruses, ticks, and worms have experimented over millions of years to create proteins that control the human immune system. We use AI to identify these proteins and engineer them into next-generation autoimmune therapies.

Our team is three PhD scientists from UCSF, UCSD, and UC Berkeley who have worked together for 3+ years in biotech. We have deep expertise in parasite biology, computational biology, and software for AI-based protein structure prediction

Company information is based on publicly available sources and is reviewed periodically. If you represent this company and would like to request a correction, contact Brel.

Explore Related Intelligence

The AI Brief

Weekly company intelligence in your inbox.

Subscribe